TABLE 1.
JAK inhibitors approved or in current development for IBD.
| Drug | Target | Gut selectivity | IBD type | Status |
| Tofacitinib | JAK1/JAK3 | No | CD UC |
Phase 2 completed (NCT00615199, NCT01393626) FDA/EMA approved |
| Peficitinib | JAK1/JAK3 | No | CD UC |
No studies Phase 2 completed (NCT01959282) |
| Upadacitinib | JAK1 | No | CD UC |
Phase 3 completed (NCT03345836), active not recruiting (NCT03345823) FDA/EMA approved |
| Filgotinib | JAK1 | No | CD UC |
Phase 3 active, not recruiting (NCT02914561), enrolling by invitation (NCT02914600) EMA approved, FDA rejected |
| Izencitinib (TD-1473) | pan-JAK | Yes | CD UC |
Phase 2 terminated (NCT03635112) Phase 2b/3 terminated (NCT03758443) |
| Ivarmacitinib (SHR0302) | JAK1 | No | CD UC |
Phase 2 completed (NCT03677648) Phase 2 completed (NCT03675477) |
| OST-122 (Oncostellae) | JAK3/TYK2/ARK5 | Yes | CD UC |
No studies Phase 1b/2a recruiting (NCT04353791) |
| Deucravacitinib (BMS-986165) | TYK2 | No | CD UC |
Phase 2 recruiting (NCT03599622) Phase 2 active, not recruiting (NCT03934216) |
| Brepocitinib (PF-06700841) | JAK1/TYK2 | No | CD UC |
Phase 2 active, not recruiting (NCT03395184) Phase 2 completed (NCT02958865) |
| Ritlecitinib (PF-06651600) | JAK3 | No | CD UC |
Phase 2 active, not recruiting (NCT03395184) Phase 2 completed (NCT02958865) |